Brian Price
Nessuna posizione attualmente
Profilo
Brian Price worked as Vice President-Pharmaceutical Development at Myonexus Therapeutics, Inc. from 2018 to 2019.
He then worked as Chief Operating Officer at Blue Water Biotech, Inc. from 2019 to 2020.
Dr. Price received his undergraduate and doctorate degrees from The Ohio State University.
Precedenti posizioni note di Brian Price
| Società | Posizione | Fine |
|---|---|---|
Myonexus Therapeutics, Inc.
 Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Myonexus Therapeutics, Inc. operates as a clinical stage company. It engages in the research and development of limb-girdle muscular dystrophy gene treatments. The company was founded by Michael Triplett and Bruce Halpryn in February 2017 and is headquartered in New Albany, OH. | Corporate Officer/Principal | 01/03/2019 |
Blue Water Biotech, Inc.
 Blue Water Biotech, Inc. Pharmaceuticals: MajorHealth Technology Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH. | Direttore operativo | 15/08/2020 |
Formazione di Brian Price
| The Ohio State University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Blue Water Biotech, Inc.
Blue Water Biotech, Inc. Pharmaceuticals: MajorHealth Technology Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH. | Health Technology |
Myonexus Therapeutics, Inc.
Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Myonexus Therapeutics, Inc. operates as a clinical stage company. It engages in the research and development of limb-girdle muscular dystrophy gene treatments. The company was founded by Michael Triplett and Bruce Halpryn in February 2017 and is headquartered in New Albany, OH. | Health Technology |
- Borsa valori
- Insiders
- Brian Price
